

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-26) VUDALIMAB
PRONUNCIATION vue da' li mab
THERAPEUTIC CLAIM Immunomodulator, antineoplastic

CHEMICAL NAMES

1. Immunoglobulin, anti-(human cytotoxic T-lymphocyte-associated protein 4) (human-Mus musculus monoclonal XmAb20717 single-chain variable fragment VL-linker-VH) fusion protein with immunoglobulin G1 (human γ 1-chain C-region C-terminal fragment), (260→227'),(263→230')- bis(disulfide) with immunoglobulin G1 anti-(human programmed cell death 1) (human-Mus musculus monoclonal XmAb20717 γ 1-chain) disulfide with human-Mus musculus monoclonal XmAb20717 κ -chain (Source: CAS)
2. Immunoglobulin half-IG G1-kappa/scFv-h-CH2-CH3, anti-[*Homo sapiens* CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)] and anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody, bispecific; gamma1 heavy chain anti-CTLA4 (1-447) [VH (*Homo sapiens* IGHV3-48*03 (90.8%) -(IGHD) -IGHJ4*01 (100%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 N114>D (209) R120>K (215) (119-216), hinge 1-15 (217-231), CH2 E1.4,L1.3>P (234), L1.2>V (235), G1.1>A (236), S29>K (267), Q84.2>E (295) (232-340), CH3 E12 (356), M14 (358), L24>D (368), K26>S (370), N44>D (384), Q97>E (418), N100>D (421), M107>L (428), N114>S (434) (341-445), CHS (446-447)) (119-447)], (221-215')-disulfide with kappa light chain anti-CTLA4, *Homo sapiens* (1'-215') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (99.0%) -IGKJ1*01 (100%)) CDR-IMGT [7.3.9] (27-33.51-53.90-98) (1'-108') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'-215')]; IG scFv-h-CH2-CH3 single chain, anti-PDCD1 (1''-480'') [scFv V-kappa-VH anti-PDCD1 (1''-249'') [V-KAPPA (*Homo sapiens* IGKV3-15*01 (80.0%) -IGHJ4*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1''-107'') -20-mer tetrakis(glycyl-lysyl-prolyl-glycyl-seryl) linker (108''-127'') -VH (*Mus musculus* IGHV6-6*02 (87.0%) -(IGHD) -IGHJ1*03 (86.7%)/*Homo sapiens* IGHV3-15*07 (81.8%) -(IGHD) -IGHJ2*01 (93.3%)) CDR-IMGT [8.10.13] (153-160.178-187.226-238) (128''-249'')] -*Homo sapiens* IGHG1*03 h-CH2-CH3, nG1m1 (250''-480'') [hinge 1-15 C5>S (254) (250-264) -CH2 E1.4,L1.3>P (267), L1.2>V (268), G1.1>A (269), S29>K (300) (265-373),CH3 E12 (389), E13>Q (390), M14 (391), S20>K (397), M107>L (461), N114>S (467) (374-478), CHS (479-480)]]; dimer (227-260'':230-263'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-S cell line, glycoform alfa (Source : WHO pINN list 123)

STRUCTURAL FORMULA

Heavy chain X (anti-CTLA4)

EVQLVESGGG	LVKPGGSLRL	SCAASGFTFS	SYTMHWVRA	PGKGLEWVSF	50
ISYDGNKYY	ADSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCARTG	100
WLGPFDYWGQ	GTLVTVSSAS	TKGPSVFPPLA	PSSKSTSGGT	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVF	SSSLGTQTYI	200
CNVNHKPSDT	KVDKKVEPKS	CDKTHTCPPC	PAPFVAGPSV	FLFPPKPKDT	250
LMISRTP EVT	CVVVDVKHED	PEVKFNWYVD	GVEVHNAKTK	PREEEYNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPSPREEMTK	NQVSLTCDVS	GFYPSDIAVE	WESDGPENN	YKTPPVLDL	400
DGSFFLYSKL	TVDKSRWEQG	DVFSCSVLHE	ALHSHYTQKS	LSLSPGK	447

Light chain X' (anti-CTLA4)

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	SSYLAWYQQK	PGQAPRLLIY	50'
GAFSRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYYCQ	QYGSSPWTFG	100'
QGTKVEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNMF	YPREAKVQWK	150'
VDNALQSGNS	QESVTEQDSK	DSTYSLSTL	TLSKADYEKH	KVYACEVTHQ	200'
GLSSPVTKSF	NRGEC				215'

Chain IG scFv-h-CH2-CH3 (anti-PDCD1)

EIVLTQSPAT	LSASPERVVT	LTCRASQSVG	NDVAWYQQKP	GQAPRLLIY	50''
ASHRYTGVPD	RFTGSGYGTE	FTLTISSVQS	EDFGVYYCQQ	DFSSPRTFGG	100''
GTKVEIKGKP	GSGKPGSGKP	GSGKPGSEVQ	LVESGGGLVK	PGGSLRLSCV	150''
ASGFTFSNYW	MNWVRQAPGK	GLEWVAEIRL	YSNNYATHYA	ESVKGRFTIS	200''
RDDSKSTLYL	QMNNLKTEDT	GVYYCTRYYG	NYGGYFDVWG	RGLTVTVSSE	250''
PKSSDKTHTC	PFCPAPPVAG	PSVFLFPPKP	KDTLMISRTP	EVTCVVVDVK	300''
HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	STYRVVSVLT	VLHQDWLNGK	350''
EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	VYTLPPSREQ	MTKNQVKLTC	400''
LVKGFYPSDI	AVEWESNGQP	ENNYKTPPV	LDSGSGFFLY	SKLTVDKSRW	450''
QQGNVFSQSV	LHEALHSHYT	QKSLSLSPGK			480''

Disulfide bridges

22-96	23''-88''	23'-89'	135'-195'	145-201	149''-225''	221-215'
227-260''	230-263''	261-321	294''-354''	367-425	400''-458''	

Glycosylation sites (N)

297	330''
-----	-------

MOLECULAR FORMULA

C₅₅₉₃H₈₅₉₀N₁₄₉₂O₁₇₂₆S₃₄

MOLECULAR WEIGHT

125.4 kDa

TRADEMARK

None as yet

SPONSOR

Xencor Inc.

CODE DESIGNATIONS

XmAb20717

CAS REGISTRY NUMBER

2329669-72-7

UNII

4I9I5X3Z6N

WHO NUMBER

11464

gbk